Literature DB >> 16220541

Peptide-stimulated DO11.10 T cells divide well but accumulate poorly in the absence of TLR agonist treatment.

Bruce S Thompson1, Veronica Mata-Haro, Carolyn R Casella, Thomas C Mitchell.   

Abstract

Immunological adjuvants increase the clonal burst size of antigen-specific T cell populations by mechanisms that remain incompletely understood. Using the DO11.10 adoptive transfer system to study peptide-stimulated T cell responses, we found that TLR agonist treatment increased the extent of cellular division undergone by responding T cells, but not by enough to explain the net increases in T cell yield that were achieved. Two novel analyses involving CFSE dye dilution analysis were used to characterize the shortfall, both of which were consistent with the idea that DO11.10 T cells are frequently lost during proliferation unless TLR agonists are present. T cell loss during clonal expansion was correlated with decreased levels of Bcl-2, but TLR agonists did not appear to afford protection by restoring levels of Bcl-2 or of cell surface IL-7Ralpha chain expression. TLR-mediated protection also failed to correlate with increased expression of Bcl-x or decreased expression of pro-apoptotic Bim. Our findings suggest that DO11.10 T cells stimulated by antigenic peptide in vivo divide well, but fail to accumulate efficiently unless TLR agonists are present.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16220541     DOI: 10.1002/eji.200526132

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  2 in total

1.  Adjuvant activity of naturally occurring monophosphoryl lipopolysaccharide preparations from mucosa-associated bacteria.

Authors:  Paula M Chilton; Diana M Hadel; Thao T To; Thomas C Mitchell; Richard P Darveau
Journal:  Infect Immun       Date:  2013-06-24       Impact factor: 3.441

2.  TRIF is required for TLR4 mediated adjuvant effects on T cell clonal expansion.

Authors:  Siva K Gandhapudi; Paula M Chilton; Thomas C Mitchell
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.